. Nevertheless, despite this significant research investment, understanding of bTBI is paralyzed by a singular lack of human neuropathology studies in those exposed to blast. As a consequence, there have been no means to evaluate the relevance of preclinical models, resulting in substantial confusion over what constitutes bTBI. Furthermore, for service members with blast exposure and TBI, it remains unclear whether their symptoms are a result of blast alone or potential accompanying blunt forces from head impact.
In this edition Shively at al 6 report their observations on the neuropathology of 8 former military personnel exposed to blast compared to small numbers of civilian controls with or without histories of TBI or opiate misuse. The authors report a distinctive astroglial pathology in all their chronic blast survival cases (greater than 6 months from injury) marked by dense astrogliosis at the boundary between cortical grey and underlying white matter, adjacent to the ventricles and subpially. Furthermore, they report reactive gliosis in a similar distribution in more acute blast survival cases (4 to 60 day survival after injury). In contrast, no similar astroglial pathology was observed in their limited series of controls, including blunt/impact TBI cases. In addition to this glial pathology, the authors report axonal pathology in all three acute and 2 of 5 late blast cases, however, without formal characterization of pattern and distribution.
Remarkably, this short series almost doubles the number of cases in the modern era describing the human neuropathology of blast TBI. Prior to this study, only 10 contemporary cases of bTBI had been described in the literature, half reporting a pathology reminiscent of CTE 7, 8 , the remainder describing axonal pathology and no evidence of CTE 9 . Thus the picture of late pathology after bTBI remained unclear. However, while these previous reports fail to reach commonality in pathology described, they do share many unavoidable weaknesses in design, most notably in the considerable heterogeneity in survivals and in exposure to non-blast TBI among their limited number of cases.
Inevitably, this latest contribution also suffers from heterogeneity in survival from injury (4 days to 9 years) and in histories of exposure to non-blast TBI ('unknown' in 6 cases) 6 , and whether the observations on specificity of this glial pathology to bTBI stand up to scrutiny in more comprehensive studies remains to be seen. Intriguingly, tau pathology reminiscent of CTE was only observed in 2 of this current series. However, as with previous neuropathological studies in bTBI, it cannot be determined if this CTE pathology represents a consequence of blast exposure alone, or is confounded by coincidental or previous non-blast injury. In this regard, one bTBI case with CTE had a history of non-blast injury described as 'unknown', whilst the second had an extensive history including sports (wrestling, boxing) and non-sports (multiple motor vehicle accidents) TBI exposure. At issue is the inability to rule out a previous TBI for almost any service member, where years of potential TBI exposure through military training, sports and accidents are more the rule than the exception. 10 Unquestionably this current study is commendable in drawing attention to the need for careful study of human tissue to further understanding of TBI. However, far from an answer to the question, 'what is blast TBI', the work instead exposes the remarkable absence of robust and informed human neuropathology studies in this field. Unquestionably, progress in TBI research, both blast and non-blast, can only benefit from efforts directed specifically to facilitate acquisition of human tissue samples linked to detailed clinical information to support robust and informative neuropathology studies.
Meanwhile, we must remain cautious in interpreting the significance of any single pathology as unique to bTBI based on small and heterogeneous case series and with limited clinical information and control comparisons. The alternative is to risk repeating the errors of the past decade and the premature assumption that CTE is a unique disease of athletes, or even exclusively tau.
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